GoodRx Projects 2026 Revenue Between $765M and $785M
GDRX sits 45% above its 52-week low of $1.77.
Summary
GoodRx Holdings has issued its revenue guidance for 2026, projecting figures between $765 million and $785 million. This forward-looking financial outlook is a critical update for investors, providing a benchmark for the company's expected performance following its 2025 results which showed mixed metrics and declining core user engagement. The guidance will be a primary driver for analyst model adjustments and investor sentiment, especially as the company recently expanded its prescription offerings. Traders will closely evaluate this guidance against market expectations to assess the company's growth trajectory and potential for future profitability.
At the time of this announcement, GDRX was trading at $2.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $880.4M. The 52-week trading range was $1.77 to $5.81. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.